Evidence map›Paper›PMID 31681477›Full record

ArticleBMJ open respiratory research2019

Antibiotics for COPD exacerbations: does drug or duration matter? A primary care database analysis.

Marie Stolbrink, Laura J Bonnett, John D Blakey

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMJ open respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05286918 (Antibiotic Stewardship Through CRP-guided Antibiotic Treatment for Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05286918 nanot yet recruitingnot on this mapstarted 2022, after this paper: background citation

Antibiotic Stewardship Through CRP-guided Antibiotic Treatment for Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

TypeinterventionalSponsorThe University of Hong KongRan2022 to 2026Enrolled1,184ConditionsAcute Exacerbation of COPD, Lung Diseases, Lung Diseases, Obstructive, Pulmonary Disease, Chronic ObstructiveArmsThe intervention (CRP-guided) group
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Marie StolbrinkInstitute of Infection and Global Health, University of Liverpool, Liverpool, UK.ORCID 0000-0001-6091-9316
Laura J BonnettDepartment of Biostatistics, University of Liverpool, Liverpool, UK.
John D BlakeyRespiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
University of Liverpool · GBCurtin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antibiotics are routinely given to people with chronic obstructive pulmonary disease (COPD) presenting with lower respiratory tract infection (LRTI) symptoms in primary care. Population prescribing habits and their consequences have not been well-described. Methods: We conducted a retrospective analysis of antibiotic prescriptions for non-pneumonic exacerbations of COPD from 2010 to 2015 using the UK primary care Optimum Patient Care Research Database. As a proxy of initial treatment failure, second antibiotic prescriptions for LRTI or all indications within 14 days were the primary and secondary outcomes, respectively. We derived a model for repeat courses using univariable and multivariable logistic regression analysis. Results: A total of 8.4% of the 9042 incident events received further antibiotics for LRTI, 15.5% further courses for any indication. Amoxicillin and doxycycline were the most common index and second-line drugs, respectively (58.7% and 28.7%), mostly given for 7 days. Index drugs other than amoxicillin, cardiovascular disease, pneumococcal vaccination and more primary care consultations were statistically significantly associated with repeat prescriptions for LRTI (p<0.05). The ORs and 95% CIs were: OR 1.28, 95% CI 1.10 to 1.49; OR 1.37, 95% CI 1.13 to 1.66; OR 1.33, 95% CI 1.14 to 1.55 and OR 1.05, 95% CI 1.02 to 1.07, respectively. Index duration, inhaled steroid use and exacerbation frequency were not statistically significant. The derived model had an area under the curve of 0.61, 95% CI 0.59 to 0.63. Discussion: The prescription of multiple antibiotic courses for COPD exacerbations was relatively common-one in twelve patients receiving antibiotics for LRTI had a further course within 2 weeks. The findings support the current preference for amoxicillin as index drug within the limitations of this observational study. Further clinical trials to determine best practice in this common clinical situation appear required.

Indexed as

AgedAged, 80 and overAmoxicillinAnti-Bacterial AgentsDisease ProgressionDoxycyclineFemaleHumansMaleMiddle AgedPrimary Health CarePulmonary Disease, Chronic ObstructiveRetrospective StudiesTime FactorsAmoxicillinAnti-Bacterial AgentsDoxycyclineanti-bacterial agentschronic obstructivelower respiratory tract infectionsprimary healthcarePulmonary Diseasetreatment failure

Identifiers

PMID31681477
PMCPMC6797433
OpenAlexW2973915319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.